TheStreet wrote that the Lambert-Eaton Myasthenic Syndrome treatment that Catalyst Pharmaceutical Partners (Nasdaq: CPRX) is developing is already available for free to patients sending the stock price tumbling 71 cents to $1.90.
Catalyst Drug Already Available
October 18, 2013 at 17:25 PM EDT